Infectiology

Tenkasi^® (Oritavancin)

Tenkasi^® (Oritavancin) is the third antibiotic in the anti-infectives portfolio of A. Menarini Pharma. With Tenkasi^®, Menarini supports the fight against multi-resistant germs.

Two medicines containing oritavancin are available: Tenkasi^® 1200 mg and Tenkasi^® 400 mg. The following is needed for the administration of a single intravenous infusion of 1200mg in adults (for paediatric patients refer to SmPC Tenkasi^® 400 mg Table 1 and to section 6.6²):

Oritavancin is a semi-synthetic glycopeptide antibiotic with a mean terminal elimination half-life of 245 h, which can be administered as a single iv infusion up to a dosage of 1200 mg (dose indicated in adults, maximum dose in pediatric population). It has three convincing mechanisms of action:

It convinces by three mechanisms of action: 

1.) Inhibition of the transglycosylation step (polymerization) of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors;

2.) Inhibition of the transpeptidation step (cross-linking) of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall; and

3.) Disruption of bacterial membrane integrity leading to depolarization, permeabilization and rapid cell death. 

Oritavancin is approved in the EU for the treatment of acute bacterial skin and skin structure infections (ABSSSI^*) against Gram-positive pathogens (incl. MRSA^#/MSSA^## and VRE^**/^###1). Tenkasi^® 400 mg² in adults and pediatric patients from 3 months and Tenkasi^® 1200 mg³ in adult patients.

References: 1 Karrine D. Brade, Infect Dis Ther (2016) 5:1–15, 2 Fachinformation, ^* ABSSSI = acute bacterial skin and skin structure infections, ^**in vitro Daten, ^#Methicillin-resistenter Staphylococcus aures, ^##Methicillin-sensibler Staphylococcus aures, ^###Vancomycin-resistente Enterokokken

AT-WEB-02-05-2024